<DOC>
	<DOCNO>NCT00651534</DOCNO>
	<brief_summary>This study examine effect formulation relative bioavailability SB-751689 ( 400 mg ) administer healthy postmenopausal woman . Subjects receive single oral dose formulation , five formulation SB-751689 test total . Blood sample take 24 hour postdose dose administration . This study provide information future possible formulation development SB-751689 Phase III .</brief_summary>
	<brief_title>To Estimate Relative Bioavailability 5 Formulations Ronacaleret Given Healthy Postmenopausal Females</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Inclusion criterion : Healthy postmenopausal woman Nonsmokers Body weight &gt; = 50 kg BMI within range 1932 kg/m2 Capable give write informed consent comply requirement restriction list consent form QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block Hispanic nonHispanic ( Caucasian ) ethnicity Exclusion criterion : Any clinically relevant biological physical abnormality find report screening , opinion investigator , clinically significant would preclude safe participation study Positive urine drug screen screen Positive urine test alcohol predose Positive HIV hepatitis B C virus screen Urinary cotinine level indicative smoking screen History smoking use nicotine containing product within one year study &gt; 10 packyear history smoke overall History regular alcohol consumption exceed 7 units/week ( 1 unit = 5 ounce wine 12 ounce beer 1.5 ounce hard liquor ) within 6 month screen History drug abuse within 6 month study Participation clinical study receive drug new chemical entity 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug Consumption red wine , grapefruit , grapefruit juice grapefruit containing product within 14 day prior first dose study medication Donation blood excess 500 mL within 56 day prior dose Evidence renal , hepatic biliary impairment History serious gastrointestinal disease History sensitivity study medication component thereof history drug allergy , opinion physician responsible , contraindicate participation . History clinically significant cardiovascular disease Medical condition might alter bone metabolism Serum parathyroid hormone ( iPTH ) test level outside reference range screen Liver function test , parathyroid hormone test CPK outside reference range screening</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Formulation Drug Study , healthy postmenopausal</keyword>
</DOC>